Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-24	US$2.550	+2.00%	130,653
26-07-23	US$2.500	-1.19%	7,507
26-07-22	US$2.530	0.00%	2,119
26-07-21	US$2.530	-2.69%	5,220
26-07-20	US$2.600	-1.14%	9,635

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.550USD

Average target price

12.00USD

Spread / Average Target

+370.59%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-24 EDT			5-day change	1st Jan Change
2.550 ^USD	+2.00%		-3.04%	+29.44%

05-08	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-09	Plus Therapeutics, Inc. Appoints Eric J. Daniels as Chief Development Officer, Effective April 20, 2026	CI

Market Cap	11.3M 9.93M 9.23M 8.47M 15.92M 1.09B 16.16M 110M 42.83M 535M 42.43M 41.51M 1.85B	P/E 2026 *	-0.96x	P/E 2027 *	-1.29x
Enterprise Value	11.3M 9.93M 9.23M 8.47M 15.92M 1.09B 16.16M 110M 42.83M 535M 42.43M 41.51M 1.85B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	96.92%	Yield 2026 *	-	Yield 2027 *	-

05-08	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-09	Plus Therapeutics, Inc. Appoints Eric J. Daniels as Chief Development Officer, Effective April 20, 2026	CI
04-07	Kiora Pharmaceuticals Inc - Enters securities purchase agreement on April 3, 2026 - SEC filing	RE
04-05	Kiora Pharmaceuticals, Inc. announced that it has received $5.000001 million in funding from ADAR1 Capital Management, LLC and another investor	CI
04-02	Kiora Pharmaceuticals, Inc. announced that it expects to receive $5.000001 million in funding from ADAR1 Capital Management, LLC and another investor	CI
04-02	Kiora Pharmaceuticals, Inc. Announces Resignation of Eric J. Daniels, M.D., MBA as Chief Development Officer, Effective April 17, 2026	CI
03-25	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-07	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-30	Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders	CI
25-09-15	Kiora Pharmaceuticals files for mixed shelf offering of up to $100 million- SEC filing	RE
25-08-08	Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-06-03	Top Midday Gainers	MT
25-06-03	Traders Eye Factory Orders, Job Openings Data as US Equity Futures Turn Flat Pre-Bell	MT

24-02-09	HC Wainwright Adjusts Price Target on Kiora Pharmaceuticals to $2 From $3.50, Maintains Buy Rating	MT
23-11-06	HC Wainwright Adjusts Kiora Pharmaceuticals' Price Target to $3.50 From $2, Keeps Buy Rating	MT
23-08-14	HC Wainwright Adjusts Price Target on Kiora Pharmaceuticals to $2 From $7, Keeps Buy Rating	MT
23-05-12	HC Wainwright Raises Kiora Pharmaceuticals' Price Target to $7 From $6, Maintains Buy Rating	MT
23-02-09	Maxim Upgrades Kiora Pharmaceuticals to Buy From Hold, Price Target is $12	MT

Kiora Pharmaceuticals, Inc. Stock

Stocks

KPRX

US49721T5074

Biotechnology & Medical Research

Valuation: Kiora Pharmaceuticals, Inc.

Chart: Kiora Pharmaceuticals, Inc.

Latest news : Kiora Pharmaceuticals, Inc.

Analysts' recommendations: Kiora Pharmaceuticals, Inc.

Press Releases: Kiora Pharmaceuticals, Inc.

News in other languages: Kiora Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Kiora Pharmaceuticals, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

07-02	Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium	NE
06-18	Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model	NE
05-08	Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update	NE
04-14	Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway	NE
04-07	Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors	NE

1 day	+2.00%
1 week	-3.04%
Current month	-3.04%
3 months	+8.51%
6 months	+20.28%
Current year	+29.44%

1 week	2.28	2.62
1 month	2.28	2.74
Current year	1.77	2.91
1 year	1.76	3.06
3 years	1.76	8.98
5 years	1.76	2,314.8
10 years	1.76	21,060.02

Manager	Title	Age	Since
Brian Strem CEO	Chief Executive Officer	46	2021-07-25
Melissa Tosca DFI	Director of Finance/CFO	46	2024-06-30
Stefan Sperl COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Praveen Tyle CHM	Chairman	66	2023-09-20
Aron Shapiro BRD	Director/Board Member	48	2021-03-31
Brian Strem BRD	Director/Board Member	46	2021-07-25

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/1/26	Melissa Tosca	Tax	Chief Financial Officer	-911	0.0206%
7/1/26	Brian Strem	Tax	Chief Executive Officer	-1,869	0.0422%
6/10/26	Erin Parsons	Free	Director	25,000	0.5641%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KIORA PHARMACEUTICALS, INC.	+2.00%	-3.04%	-14.72%	-52.88%	11.3M
ARGENX SE	+0.93%	+6.97%	+59.60%	+68.35%	57.28B
WUXI APPTEC CO., LTD.	-1.92%	+6.03%	+40.64%	+83.42%	54.99B
INSMED INCORPORATED	-0.46%	-1.29%	+2.86%	+428.78%	23.18B
BIONTECH SE	-2.97%	-2.35%	-22.53%	-16.40%	22.59B
WUXI BIOLOGICS (CAYMAN) INC.	-0.36%	+5.73%	+24.13%	-6.24%	20.46B
GENMAB A/S	-1.34%	+0.51%	+26.03%	-29.41%	17.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.44%	+5.67%	+38.77%	+504.71%	15.67B
PHARMAESSENTIA CORPORATION	-1.30%	-5.02%	+170.77%	+291.37%	14.46B
EXELIXIS, INC.	-0.50%	-0.98%	+21.43%	+180.07%	13.92B
Average	-0.74%	+0.84%	+34.70%	+145.18%	24.01B
Weighted average by Cap.	-0.87%	+2.10%	+39.70%	+133.49%

	2026 *	2027 *
Net sales	-	-
Net income	-11.94M -10.49M -9.75M -8.95M -16.81M -1.15B -17.07M -116M -45.24M -565M -44.82M -43.85M -1.95B	-20.34M -17.87M -16.61M -15.25M -28.65M -1.96B -29.09M -197M -77.08M -963M -76.36M -74.71M -3.33B
Net Debt	-	-